BETA Technologies launches IPO of 25 million shares priced $27-$33
Patrick G. Enright, a director at Zenas BioPharma, Inc. (NASDAQ:ZBIO), acquired shares of common stock in the company worth $2.25 million on October 9, 2025. The purchase comes amid strong momentum for ZBIO, which has surged over 27% in the past week and more than 210% over the last six months.
The transactions involved the purchase of 105,265 shares at $19.00 and 11,990 shares at $20.85. The purchases were part of a Securities Purchase Agreement, where Enright bought 11,990 shares directly and Longitude Venture Partners IV, L.P. ("LVPIV"), where Enright is managing member, bought 105,265 shares.
Following the transaction, Enright directly holds 11,990 shares and indirectly holds 1,832,669 shares.
In other recent news, Zenas Biopharma has entered a significant licensing agreement with InnoCare Pharma, securing global rights to develop and commercialize three autoimmune product candidates, including orelabrutinib, a BTK inhibitor in Phase 3 development for multiple sclerosis. This deal, valued at over $2 billion, includes up to $100 million in upfront and near-term milestone payments and up to 7 million shares of Zenas common stock. The agreement expands Zenas’s pipeline, adding new candidates beyond its existing portfolio. H.C. Wainwright has maintained a Buy rating for Zenas Biopharma, with a $30.00 price target, highlighting the strategic expansion of its pipeline. Additionally, Zenas Biopharma has secured rights to a novel oral IL-17AA/AF inhibitor and an oral brain-penetrant TYK2 inhibitor. In a separate development, Zeta Network Group announced a strategic partnership with SOLV Foundation to enhance its Bitcoin-centric financial initiatives. This partnership will utilize SOLV’s platform, which holds $2.5 billion in total value locked, to improve the efficiency of Zeta’s Bitcoin holdings. Under the agreement, Zeta’s Bitcoin assets will be managed by a regulated third-party custodian, ensuring transparency and auditability.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.